Evidence map›Paper›PMID 40261250›Full record

ArticleThe Journal of experimental medicine2025

Vaccinology: Getting our modernization act together.

Ofer Levy

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Immune development in early life.Nature immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ofer LevyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital , Boston, MA, USA.ORCID 0000-0002-5859-1945

Funding

Proteomics and Metabolomics Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthmaU19AI168643 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OFER LEVY · 2022 to 2026
$10.0M
VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES75N93023C00040 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI DOWLING, DAVID JAMES · 2023 to 2025
$4.3M
VACCINE ADJUVANT DISCOVERY PROGRAM (VADP)75N93024C00020 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2024 to 2025
$2.5M
Immune Development in Early Life U19AI168643National Institute of Allergy and Infectious DiseasesNIAID NIH HHS 75N93023C00040NIAID NIH HHS 75N93024C00020NIAID NIH HHS U19 AI168643NIH HHS
6 · The paper itself

Abstract

Ofer Levy, Director, Precision Vaccines Program at Boston Children's Hospital, reflects on implications of the new FDA Modernization Act 2.0 on accelerating drug and vaccine discovery and development.

Indexed as

Vaccine DevelopmentVaccinesVaccinologyDrug DiscoveryHumansUnited StatesUnited States Food and Drug AdministrationVaccines

Identifiers

PMID40261250
PMCPMC12013515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.